Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · IEX Real-Time Price · USD
38.24
-0.34 (-0.88%)
At close: May 17, 2024, 4:00 PM
36.56
-1.68 (-4.39%)
After-hours: May 17, 2024, 5:43 PM EDT
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for TARS stock have an average target of 50.83, with a low estimate of 30 and a high estimate of 61. The average target predicts an increase of 32.92% from the current stock price of 38.24.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TARS stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $57 → $61 | Strong Buy | Maintains | $57 → $61 | +59.52% | May 13, 2024 |
| Barclays | Barclays | Buy Maintains $50 → $60 | Buy | Maintains | $50 → $60 | +56.90% | May 10, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $59 → $61 | Buy | Maintains | $59 → $61 | +59.52% | May 9, 2024 |
| Jefferies | Jefferies | Strong Buy Maintains $30 → $44 | Strong Buy | Maintains | $30 → $44 | +15.06% | Mar 6, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $19 → $30 | Hold | Maintains | $19 → $30 | -21.55% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
96.73M
from 17.45M
Increased by 454.41%
Revenue Next Year
196.60M
from 96.73M
Increased by 103.25%
EPS This Year
-4.48
from -4.62
EPS Next Year
-2.18
from -4.48
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 111.4M | 237.8M | 420.0M | 630.0M | 787.5M |
| Avg | 96.7M | 196.6M | 347.3M | 559.3M | 690.0M |
| Low | 73.5M | 171.5M | 268.5M | 486.8M | 590.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 538.4% | 145.9% | 113.6% | 81.4% | 40.8% |
| Avg | 454.4% | 103.3% | 76.7% | 61.0% | 23.4% |
| Low | 321.3% | 77.3% | 36.6% | 40.2% | 5.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -3.70 | -0.37 | 2.50 |
| Avg | -4.48 | -2.18 | 1.08 |
| Low | -5.33 | -3.63 | -1.76 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.